CareDx, Inc. develops, markets, and delivers a diagnostic surveillance solution for heart transplant recipients to help clinicians make personalized treatment decisions throughout a transplant patient's lifetime. It provides AlloMap, a noninvasive blood test used to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection at the time of testing in conjunction with standard clinical assessment. The company also offers AlloMap Molecular Expression Testing, an in vitro diagnostic multivariate index assay test service performed in a single laboratory assessing the gene expression profile of RNA isolated from peripheral blood mononuclear cells. It markets and sells its products through distribution partners in the United States, Canada, and Europe. CareDx, Inc. was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in April 2014. The company was incorporated in 1998 and is based in Brisbane, California.